Zeltia SA: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
Zeltia SA Announces Negative Results From Phase II Trial Of Alzheimer Treatment-Reuters
Reuters reported that Zeltia SA’s Phase II trial of a drug for the treatment of Alzheimer did not achieve the intended objectives. The study evaluated the efficacy of Noscira’s drug tideglusib, versus placebo plus standard treatment in patients with mild-stage of Alzheimer.
Latest Developments for Zeltia SA
- Zeltia SA's Subsidiary Noscira SA To Be Dissolved
- Zeltia SA’s Pharma Mar Receives 14 New Marketing Authorizations For Yondelis In 10 Countries-Reuters
- Zeltia SA’s Subsidiary, Noscira SA, To Propose Dissolution
- Zeltia SA Announces Results From Phase II Trial Of Noscira's Alzheimer's Treatment-Reuters
Latest Key Developments in Biotechnology
- Share this
- Digg this